Zoetis Reports Third Quarter 2015 Results

Go back to Zoetis Reports Third Quarter 2015 Results

Zoetis (ZTS) PT Lifted to $58 at Piper Jaffray on Solid Q3 and Ahead of Simparica Approval

November 4, 2015 8:52 AM EST

Piper Jaffray analyst Kevin Ellich reiterated an Overweight rating and boosted his price target on Zoetis Inc. (NYSE: ZTS) to $58.00 (from $55.00) following solid Q3 results. The analyst sees Simparica approval coming soon.

Ellich commented, "ZTS' Q3 results were impressive as the company... More

Zoetis (ZTS) Announces 3Q Beat and Raise Along with PHARMAQ Deal; Guggenheim Reiterates Buy

November 3, 2015 1:17 PM EST

Guggenheim reiterated a Buy rating and $60.00 price target on Zoetis Inc. (NYSE: ZTS) following the company's 3Q15 earnings results. ZTS reported 3Q15 EPS of $0.50, $0.10 higher than consensus, and then increased its '15 and '16 EPS guidance to $1.70-$1.74 from $1.63-$1.68 and $1.84-$1.94 from $1.81-$1.93, respectively. The release also included the announcement of a deal with PHARMAQ. Management stated that PHARMAQ... More

Zoetis (ZTS) Tops Q3 EPS by 10c; Issues Solid Outlook

November 3, 2015 7:08 AM EST

Zoetis (NYSE: ZTS) reported Q3 EPS of $0.50, $0.10 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.18 billion.

Zoetis sees FY2015 EPS of $1.70-$1.74, versus the consensus of $1.66. Zoetis sees FY2015 revenue of $4.7-4.75 billion, versus the consensus of $4.76 billion.

Zoetis sees FY2016 EPS of $1.84-$1.94, versus the consensus of $1.90. Zoetis sees FY2016 revenue of $4.75-4.875 billion, versus the consensus of $4.76 billion.

Zoetis sees FY2017 EPS of... More